ArticleLeukemia2005
A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.
Article in Leukemia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 66 citations in OpenAlex.
- Digital and Manual Assessment of Intrafollicular Ki-67,Diagnostics (Basel, Switzerland) · 2026Article
- Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.Cancers · 2025Review
- The pathobiology of follicular lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2023Article
- Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma.Nature communications · 2023Article
- Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- High intratumoral expression of vimentin predicts histological transformation in patients with follicular lymphoma.Blood cancer journal · 2019Article
- Development of follicular lymphoma after treatment of diffuse large B-cell lymphoma: two case reports with review of literature.International journal of clinical and experimental pathology · 2018Article
- Unmet needs in the first-line treatment of follicular lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Review
- P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia.Frontiers in pharmacology · 2016Review
- A high complex karyotype involving eleven chromosomes including three novel chromosomal aberrations and monoallelic loss ofMolecular cytogenetics · 2016Article
- Article
- Pathogenesis of follicular lymphoma.The Journal of clinical investigation · 2012Review
- Article
- Article
- Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma.Haematologica · 2009Article
- p37Ing1b regulates B-cell proliferation and cooperates with p53 to suppress diffuse large B-cell lymphomagenesis.Cancer research · 2008Article
- Article
- Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma.Leukemia · 2007Article
- Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic-pathologic-clinical correlations.Journal of cancer research and clinical oncology · 2007Article
- Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.British journal of haematology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of TP53 mutation in transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (t-FL) was examined in a panel of 91 lymph node biopsies derived from 29 patients pre- and post-transformation. The entire TP53 coding sequence was screened and immunocytochemistry performed to determine expression of p53 and its key regulator MDM2. A total of 10 mutations were detected in eight patients (28%), although none were present at FL diagnosis. Mutations were not detected solely at the time of transformation; in three patients, mutated TP53 arose in at least one antecedent FL sample (6 months, 2.5 years and 4 years prior to transformation). Loss of heterozygosity at the TP53 locus occurred in 2/20 informative patients (only in t-FL samples). p53 staining was positive in 82% (9/11) of available biopsies with a missense mutation, and negative in 71% (45/63) with wtTP53. MDM2 expression was significantly higher in t-FL samples (mean 72% positive; 95% confidence interval (95% CI) 68-76%) than FL (mean 58% positive; 95% CI 54-62%) (P<0.001) but did not correlate with TP53 status. TP53 mutation has only a limited role in the transformation of FL, exerting a heterogeneous influence upon phenotypic change. In contrast, dysregulation of MDM2 is frequent and may provide a more rational therapeutic target..
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.